Non-invasive Diagnostics of Microbial Keratitis

NCT06364878 | Recruiting

• 1 other identifier: 813533
• Study Type: observational
• Target: 125
• Locations: 1 country
• Sites: 1

Brief Summary

Infectious keratitis is a significant cause of partial vision loss and blindness and places a large burden on eye care professionals. One of the main challenges for the ophthalmologist when presented with a case of suspected microbial keratitis is the determination of the subtype of keratitis. It must be determined whether the origin of the infection is bacterial, viral, fungal, or parasitic, in order to prescribe a correct, effective treatment aimed at the causative pathogen. In daily practice this can be challenging, and general treatments with antibiotics are prescribed. Some cases then experiences deterioration, resulting in more patients visits and further rounds of invasive treatments and progressive vision deterioration. This project is designed to break this cycle of nonspecific diagnosis, suboptimal treatment, and progressive worsening of vision with increased interventions. New, advanced diagnostics will be brought into the clinic to provide additional information which, if our hypothesis is correct, will result in more rapid and accurate diagnosis of the keratitis subtype. This will translate into earlier administration of a more targeted treatment, avoiding the repeated round of non-targeted treatment and progressive worsening of the patient's vision. This can directly reduce to number of clinic visits and specialist time required for treatment and follow-up of keratitis, knowledge of how the eye responds to various microbes by initiating a specific cascade of molecular inflammatory signals and changes in protein expression in the tear film. Using in vivo confocal microscopy (IVCM) we will document the cellular status of the cornea and identify microbes infecting the cornea in real-time. Secondly, tear samples will be obtained from patients with keratitis to evaluate and quantify the molecular cytokine signatures associated with specific microbial species, confirmed by microbiological culture. We will for the first time develop cytokine profiles for the various types of infection, identifying diagnostic cytokines which in the longer term can lead to development of rapid point-of-care biomarker diagnostics. The project aims are translated into the following hypotheses: H1: In vivo confocal microscopy imaging features detect microbial keratitis consistent with clinical assessment and outcome at a greater frequency than microbiological culture results. H2: Cytokine profiles (or a subset of molecules) in the eye are specific for viral, bacterial, fungal, or amoebic keratitis; and H3: A combination of in vivo confocal microscopy and molecular profiling of the tear film can yield a specific keratitis diagnosis closely matching the clinical progression and outcome of keratitis.

Conditions

Infectious Keratitis

Outcome Measures

Primary Outcomes (1)

• IVCM findings and cytokine profile in infectious keratitis is specific for the different microbial subtypes.

  A combination of in vivo confocal microscopy and molecular profiling of the tear film can yield a specific keratitis diagnosis closely matching the clinical progression and outcome of keratitis.

  18 months

Study Arms (2)

Patents with suspected infectious keratitis

Diagnostic Test: In vivo confocal microscopy; Diagnostic Test: Tear film sampling

Healthy controls

Diagnostic Test: In vivo confocal microscopy; Diagnostic Test: Tear film sampling

Interventions

In vivo confocal microscopy DIAGNOSTIC_TEST

The patients cornea will be examined non-invasively by IVCM

Also known as: IVCM

Healthy controls; Patents with suspected infectious keratitis

Tear film sampling DIAGNOSTIC_TEST

Patients tear film will be collected and stored at -80 degrees for analysis

Healthy controls; Patents with suspected infectious keratitis

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with clinically suspected infectious keratitis, over 18 years of age, presenting to the ophthalmology department at Arendal hospital.

You may qualify if:

• Clinically suspected infectious keratitis in patients over 18 years of age
• Patients with acceptable travel distance to the hospital
• Patients accepting to be part of the study

You may not qualify if:

• Previously diagnosed infectious keratitis during the last 6 months
• Over 50 percent thinning of the cornea
• Previous use of antibiotics (other than Chloramphenicol)

Sponsors & Collaborators

• Sorlandet Hospital HF: lead

Study Sites (1)

Sorlandet hospital

Arendal, Norway

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Tear film on Schirmers test stored in microtubes at -80°C for biochemical analyses.

Study Officials

• Neil Lagali

  Sorlandet Hospital HF

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Ingvild M Bakken

CONTACT

37014856; ingvild.mygland.bakken@sshf.no

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Target Duration: 3 Months
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 10, 2024
• First Posted: April 15, 2024
• Study Start: August 23, 2023
• Primary Completion: March 1, 2025
• Study Completion (Estimated): April 8, 2028
• Last Updated: April 15, 2024

Record last verified: 2023-04

Locations

NO (1)